Revenue for the quarter was ₹341 Cr. Gross margin for the quarter was 42.4% (compared to 48.1% Q1 FY22). EBITDA margin pre-ESOP 5.9% (compared to 11.2% Q1 FY22) and post-ESOP EBITDA margin of 3.2% (compared to 6.3% Q1 FY22). Revenue from API for the quarter was ₹88.8Cr (2.5% decline YOY). API momentum was impacted due …
Operational highlights The company had a steady operational and financial performance in Q1FY23, in the backdrop of inflationary headwinds leading to higher raw material and energy costs during the quarter. During the quarter the company witnessed significant increase in raw material cost as well as energy cost. However the company has witnessed significant improvement in …
The company sold 108,922 MT of plastic goods and achieved net product turnover of INR 2,169 crore during the first quarter of the current year against sales of 71,264 MT and net product turnover of INR 1,310 crore in the corresponding quarter of previous year, achieving volume and product value growth of about 53% and …
Released 185 new songs vs 73 last qtr (Q4 22). Highest in any qtr till now. 142 non film songs and 43 film songs. Next qtr acquisition costs will increase. Payments are done in parts to acquire the Music : 20-25% – Signing 50% – Audio and Video Release 25% – Final Content Release Tips …
The demerger of Piramal enterprises is expected to be completed by Q3 FY2023 Q1 FY2023 Performance: Pharma revenues CDMO revenues : Q1 FY23 Revenue grew 8% YoY : Despite the global challenges in biotech funding, company is witnessing high RFP activity from existing and new clients according the management Major Issues in the CDMO business: …
Revenue for the quarter was ₹1539 Cr (20% growth YoY). The EBITDA margin was 29.5% for the quarter despite inflationary pressures. They saw significant growth in their CDMO business (196% growth YoY, 60% growth QoQ) which helped offset the muted performance of the ARV business. RM prices remain elevated due to the geopolitical situation and …
Revenue for the quarter was ₹644 Cr (8% growth YoY), EBITDA margin for the quarter was 28.5% The revenue growth for the quarter was muted compared to the same quarter last year as there was significant sales of Remdesivir last year. Excluding the Remdesivir business, revenues grew by 30% YoY and PAT grew by …
Total revenue registered a y-o-y growth of 23% to Rs. 1,190 cr from Rs. 965 cr, but down 25% q-o-q from 1595cr. Degrowth in EBITDA was 40% to 126cr in Q1 23 from 210 cr in Q1 22. Margins also dropped to 11% from 22%. Reasons for fall in EBITDA were because of Weak agri …
Revenue in Q1 FY23 grew by 59% to 218.9 crs from 137.6 crs in Q1 Fy22 but down 11.5% sequentially from 247.5 crs. Volume grew 38% to 14406MT from 10200MT in Q1 FY22. EBITDA was 20.0 crs as against 17.4 crs y-o-y but dropped from 28.4 cr in previous quarter. Margin also dropped to 9.2% …
Despite inflation and rising input prices, the company reported a good number of bookings in this quarter. Management stated they are witnessing turnaround in hospitality as well as retail projects. The Oberoi Group predicts growth in realizations to continue as ready to move in demand has already absorbed. Financials As compared with Q4 FY22, the …